Genmab A/S Stock

Genmab A/S Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Genmab A/S (GMAB.CO) as of Aug 14, 2026 is -85.66. In the previous year, Cash Conversion Cycle (CCC) was -99.49 — a change of -13.90% (higher).

Cash Conversion Cycle

-85.66

YoY

-13.90%

Last updated:

Cash Conversion Cycle (CCC) of Genmab A/S is 2026 -85.66 . Cash Conversion Cycle (CCC) of Genmab A/S was 2025 -99.49 . It decreases by -13.90% higher compared to the previous year.
Access this data via the Eulerpool API

Genmab A/S Stock analysis

What does Genmab A/S do? Genmab A/S is a Danish biotechnology company specializing in the discovery and development of antibody therapies for cancer and other serious diseases. The company was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab A/S stock

Cash Conversion Cycle (CCC) of Genmab A/S is -85.66 in 2026.

Cash Conversion Cycle (CCC) of Genmab A/S changed from -99.49 to -85.66, representing a -13.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Genmab A/S since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Genmab A/S with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

Profitability — Genmab A/S

All Key Metrics — Genmab A/S